Abstract
AbstractPlasma activated liquid (PAL) is an emerging cancer treatment. Two prostate cell lines and one melanoma cell line were used in clonogenic assays to assess the cytotoxicity of PAL and radiation individually and in combination, using the multiplicative survival method to quantify interactions between the treatments. PAL applied before a dose of radiation synergistically increases cytotoxicity in cancer cells, while in immortalized normal cells, the combined treatment was found to be antagonistic. These results demonstrate the potential to improve the therapeutic window of cancer treatment, giving a higher cancer response rate with less toxicity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
